The Anti-Lysoganglioside GM1 test measures autoantibodies directed against lysoganglioside GM1, a glycolipid found in the membranes of neurons throughout the central and peripheral nervous system. These molecules play an important role in maintaining nerve structure, communication, and signal transmission. When the immune system produces antibodies that mistakenly target lysoganglioside GM1, it may interfere with normal neuronal function and contribute to immune-mediated neuroinflammation.
Elevated anti-GM1 titers have been observed in individuals experiencing sudden-onset or severe neuropsychiatric symptoms, including obsessive-compulsive behaviors, anxiety, tics, movement abnormalities, emotional dysregulation, and cognitive or behavioral regression. These antibodies are part of the immunological patterns described in PANS (Pediatric Acute-Onset Neuropsychiatric Syndrome), PANDAS, Sydenham chorea, and other post-infectious or autoimmune neurological conditions.
Because lysogangliosides are present on neuronal cell surfaces, antibodies against them may alter how neurons communicate, potentially affecting dopamine pathways and other neurotransmitter systems. This marker is one component of the Autoimmune Brain Panel™, a specialized test designed to identify neuro-immune activation affecting brain function.
On its own, an elevated anti-GM1 level does not diagnose any specific disorder, but it provides valuable supporting information when interpreted alongside other neuronal autoantibodies (DRD1, DRD2L, anti-tubulin), CaM Kinase II activation, symptom history, and recent infections such as strep or mycoplasma.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.